
Looking to sell Georgiamune stock or options?
Operator of a clinical-stage biotechnology company intended to reprogram immune signaling pathways to restore immune homeostasis and fight cancer and autoimmune diseases. The company offers a proprietary target discovery platform that develops first-in-class targeted immunomodulatory therapeutics including novel monoclonal antibodies and small molecules designed to activate or down-modulate key immune pathways, enabling patients and healthcare providers to overcome treatment resistance, restore proper immune function and access effective, targeted treatments for hard-to-treat cancers and autoimmune conditions.

Prevail Private Capital, Hawktail, CJNV BioVentures, Catalio Capital Management, Lauder Partners, Parker Institute for Cancer Immunotherapy, Mubadala Capital, Verition Fund Management, Alexandria Venture Investments, Mamoura Diversified Global Holding.